Other
Deferred taxes
Vertex Pharmaceuticals Deferred taxes remained flat by 0.0% to -$127.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 46.4%, from -$87.20M to -$127.70M. Over 2 years (FY 2023 to FY 2025), Deferred taxes shows relatively stable performance with a -2.4% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
How to read this metric
Changes indicate shifts in the timing of tax liabilities, often driven by capital expenditures or changes in tax regulations.
Detailed definition
This metric reflects the tax effects of temporary differences between the carrying amounts of assets and liabilities for...
Peer comparison
Standard line item in the cash flow statement or tax reconciliation for all corporations.
Metric ID:
other_deferred_income_tax_expense_benefitHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | -$536.50M | -$348.80M | -$510.80M |
| YoY Change | — | +35.0% | -46.4% |
Range-$536.50M – -$348.80M
CAGR-2.4%
Avg YoY Growth-5.7%
Median YoY Growth-5.7%
Deferred taxes at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's deferred taxes?
- Vertex Pharmaceuticals (VRTX) reported deferred taxes of -$127.70M in Q4 2025.
- How has Vertex Pharmaceuticals's deferred taxes changed year-over-year?
- Vertex Pharmaceuticals's deferred taxes decreased by 46.4% year-over-year, from -$87.20M to -$127.70M.
- What is the long-term trend for Vertex Pharmaceuticals's deferred taxes?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's deferred taxes has grown at a -2.4% compound annual growth rate (CAGR), from -$536.50M to -$510.80M.
- What does deferred taxes mean?
- The tax expense or benefit that will be paid or realized in future periods due to current accounting differences.